Data from two midstage clinical trials show that Halozyme Therapeutics' insulin PH20 was as effective as Eli Lilly and Co.'s Humalog in controlling blood glucose levels in patients with type 1 and type 2 diabetes. Halozyme is seeking partnerships and opportunities worldwide to make its insulin available.

Related Summaries